The metabolism of CYP2C9 and CYP2C19 for gliclazide by homology modeling and docking study.
Article Details
- CitationCopy to clipboard
Yao Y, Han WW, Zhou YH, Li ZS, Li Q, Chen XY, Zhong DF
The metabolism of CYP2C9 and CYP2C19 for gliclazide by homology modeling and docking study.
Eur J Med Chem. 2009 Feb;44(2):854-61. doi: 10.1016/j.ejmech.2008.04.015. Epub 2008 May 2.
- PubMed ID
- 18541345 [ View in PubMed]
- Abstract
With homology modeling techniques, a 3D structure model of CYP2C19 was built and refined with molecular mechanics and molecular dynamics simulations. The refined model was assessed to be reasonable by Profile-3D and PROCHECK programs. With the aid of the automatic molecular docking, one substrate and two inhibitors were docked to CYP2C19 by InsightII/Affinity program. The docking results, which are in well agreement with the reported results, demonstrate that the refined model of CYP2C19 is reliable. Then, with the refined model of CYP2C19 and the crystal structure of CYP2C9, the metabolisms of them for gliclazide in two different metabolic pathways were studied and the results show that both enzymes have more favorable interaction energies and stronger affinity with gliclazide in methylhydroxylation pathway than in 6beta-hydroxylation pathway. It is exciting that substrate inhibition phenomenon can be found in metabolisms of CYP2C9 and CYP2C19 for gliclazide in two metabolic pathways. Gliclazide can change the conformation of the active sites and decrease obviously the affinities between gliclazide in the active site and enzymes when it is docked in the second active sites in CYP2C9 and CYP2C19. These results are in well agreement with the kinetic experimental results.
DrugBank Data that Cites this Article
- Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Gliclazide Cytochrome P450 2C19 Protein Humans UnknownSubstrateDetails Gliclazide Cytochrome P450 2C9 Protein Humans UnknownSubstrateDetails